Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE), an emerging growth company incorporated in Delaware, filed a Current Report on Form 8-K dated November 8, 2024. The filing reports the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics and Transaction Details
This filing does not report periodic financial results such as revenue, profit, or cash flow. The primary financial metric disclosed relates to a new capital raising mechanism:
- Agreement Type: At-the-Market (ATM) Offering Agreement.
- Counterparty: H.C. Wainwright & Co., LLC (acting as sales agent or principal).
- Maximum Offering Size: Up to $3.0 million in aggregate offering price.
- Commission: 3.0% of gross proceeds from sales.
- Use of Proceeds: General corporate purposes, including preclinical studies, clinical trials, and advancement of product candidates.
Material Changes
The material change reported is the execution of the Sales Agreement on November 8, 2024. This agreement grants the Company the option, but not the obligation, to sell shares from time to time. The issuance will be made pursuant to a prospectus supplement to the Company's Registration Statement on Form S-3, which became effective on February 2, 2024.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds to advance its product pipeline. The agreement allows for sales based on the Company's instructions regarding price, time, or size limits.
Termination: The Sales Agreement may be terminated by either party upon providing notice, subject to limitations within the agreement.
Risks and Contingencies: The filing explicitly states that the 8-K does not constitute an offer to sell securities. Sales are subject to applicable state and federal laws, rules, and regulations. The Company is not obligated to sell any shares under the agreement.
Investor Verification Checklist
- Verify the current market price of APRE common stock to assess potential dilution impact if the full $3.0 million is sold.
- Review the Company's most recent Form 10-K or 10-Q for actual cash balances and burn rate to determine the urgency of this capital raise.
- Confirm the status of the Form S-3 registration statement referenced in the filing.
- Monitor future filings for actual sales activity and the amount of shares issued under this agreement.